Researchers have established an optimized and streamlined genome engineering workflow that achieves high-efficiency CRISPR/Cas9 editing directly within pure-background non-obese diabetic mice, eliminating the prolonged multi-generational breeding schemes traditionally required to introduce targeted mutations. The non-obese diabetic mouse, specifically the NODShiLtJ strain, serves as a premier biomedical model for investigating human autoimmune type 1 diabetes, underlying immunophenotypes, viral pathogenesis, and oncological mechanisms. Historically, genetic manipulation on this background has presented severe logistical hurdles because natural reproductive efficiency in the strain is remarkably low, animals have a shortened fertile lifespan due to progressive autoimmune beta-cell destruction beginning as early as two to three weeks of age, and no robust germline-competent embryonic stem cell lines exist. To circumvent these reproductive and physiological barriers, researchers routinely generated desired mutations in permissive inbred lines like C57BL6 and spent eighteen to twenty-four months repeatedly backcrossing progeny onto the NOD background. The newly validated protocol bypasses this entire backcrossing phase, enabling the generation of fully characterized, sequence-verified genetically modified NOD lines in twelve to fourteen weeks.
The biological value of the NOD background extends across immunology, endocrinology, and infectious disease modeling because these animals carry numerous specific genetic susceptibilities alongside profound innate and adaptive immune abnormalities. Beyond classical spontaneous autoimmune diabetes, NOD mice exhibit defective antigen-presenting cell immunoregulatory functions, impaired natural killer cell activity, atypical macrophage cytokine production, altered T-lymphocyte regulation, and defective tissue wound healing. Furthermore, the NODShiLtJ strain serves as the essential genetic foundation for severely immunodeficient derivatives, notably NOD/SCID Gamma and NOD/SCID Rag strains, which represent foundational platforms for human cell engraftment, cancer xenografts, and infectious disease investigations including coronavirus modeling. Generating multigene alterations or precise disease-associated knock-in alleles directly within these immunodeficient platforms is critical for dissecting disease mechanisms, yet investigators previously faced formidable bottlenecks in embryo recovery, fragile zygote development, and unpredictable superovulation kinetics that impeded direct microinjection or electroporation efforts.
To overcome the strain’s reproductive constraints, the research team systematically examined the superovulation kinetics and mating behaviors of female NODShiLtJ donors at four and six weeks of age. Natural mating in this strain typically yields low fertilization rates, while alternative methods such as in vitro fertilization require specialized micromanipulation, cumbersome overnight working hours, and complex timing schedules that are difficult to standardize in routine animal facilities. The investigators tested a defined hormonal schedule in which donor females received five international units of pregnant mare serum gonadotropin between 8:00 AM and 12:00 PM, followed forty-six hours later by an injection of human chorionic gonadotropin before being immediately paired with eight- to ten-week-old stud males. Although six-week-old females demonstrated higher rates of successful copulation and higher overall oocyte numbers, the average yield of viable, injectable embryos remained comparable between age groups, producing approximately twenty-two embryos per four-week-old female and twenty-four embryos per six-week-old female. Crucially, four-week-old donors avoided two weeks of colony housing costs and produced significantly higher numbers of successfully gene-edited pups per female donor, establishing younger mice as a superior embryo source.
A critical technical insight uncovered during embryo collection was the distinctive developmental delay characteristic of NODShiLtJ zygotes immediately following isolation. When embryos were harvested between 9:00 AM and 11:00 AM after mating, microscopic inspection revealed that their pronuclei were diminutive and poorly defined, rendering immediate pronuclear microinjection hazardous and technically inefficient. Previous attempts in published literature had noted that premature microinjection of poorly visible pronuclei led to mechanical trauma, zygotic lysis, and developmental arrest. To resolve this hurdle without adopting overnight procedures, the investigators introduced a post-harvest incubation step of two to three hours at 37 degrees Celsius in culture medium. By approximately seventy-five to seventy-six hours after the initial pregnant mare serum gonadotropin injection, the pronuclei expanded into prominent, clearly visible structures amenable to continuous-flow microinjection under high-magnification microscopy, vastly improving post-injection survival and developmental competency.
The efficacy of direct pronuclear microinjection was validated across distinct genetic loci, beginning with targeted knockout of the Gasdermin D gene using custom guide RNAs designed to excise intron 1 and exon 2 containing the initiation codon. Embryos recovered from four-week-old and six-week-old superovulated donors were microinjected with Cas9 enzyme and specific guide RNAs, resulting in comparable post-injection survival rates of 59.8 percent and 60.6 percent, respectively. Following surgical transfer into the oviducts of pseudo-pregnant CD1 recipient females, the four-week-old donor cohort yielded eighteen live pups, of which sixteen animals—amounting to an 88.8 percent editing efficiency—carried the desired genomic deletion. By comparison, the six-week-old cohort produced five live pups, of which four animals, or 80.0 percent, were positive for the targeted deletion. Polymerase chain reaction amplification confirmed the presence of shortened diagnostic amplicons, while statistical analysis confirmed that four-week-old females yielded a significantly higher number of gene-edited pups per donor female, recorded at 10.06 plus or minus 0.30 compared to 0.26 plus or minus 0.03 in older animals.
The microinjection approach was subsequently tested on a second target, the transient receptor potential cation channel subfamily member 5 gene, designated Trpm5. Investigators microinjected 123 total embryos across two experimental cohorts using distinct pairs of guide RNAs targeted to delete exon 3 entirely. In the first cohort, utilizing guide RNAs designated number one and number three, seventy-five embryos yielded twelve live-born pups, with eleven animals testing positive for the targeted genomic deletion, representing a 91.66 percent targeting success rate. The second cohort, employing guide RNAs numbered two and three across eighty-one injected embryos, produced two live pups, one of which carried the deletion, demonstrating a 50.0 percent modification rate. Across both microinjection sets, overall editing efficiency reached 86.0 percent among live pups, confirming that pronuclear delivery yields consistently robust knockout rates across independent genomic targets when pronuclear visibility is appropriately managed prior to delivery.
In parallel, the researchers evaluated electroporation as a high-throughput alternative to pronuclear microinjection, deploying a multi-pulse electroporation system to introduce gene editing reagents into up to 150 zygotes simultaneously. Electroporation circumvents physical needle penetration, typically yielding nearly 100 percent embryo survival without requiring the removal or softening of the zona pellucida with acidic solutions. When applied to Trpm5 knockout using sixty-three embryos and the first guide RNA combination, the procedure yielded seven live pups, six of which exhibited the target deletion, representing an 85.7 percent editing rate. A second electroporation cohort of fifty-three embryos using the alternate guide pair produced four pups with three carrying the deletion, achieving 75.0 percent efficiency. However, locus-dependent variation emerged when targeting Gasdermin D via electroporation: out of 140 treated embryos, 138 survived and yielded fifty-four live pups, but ear punch screening identified only a single gene-edited individual, demonstrating that direct pronuclear injection remains markedly superior for certain challenging target loci.
The study further expanded the platform to precise knock-in mutagenesis within the angiotensin-converting enzyme 2 gene, an essential receptor for severe acute respiratory syndrome coronaviruses. To model viral susceptibility, the team designed homology-directed repair strategies to substitute five native mouse amino acids in exon 9 with human counterparts—A329E, A337G, G339V, V342A, and H353K—using either a 533-nucleotide single-stranded DNA donor template or a 186-nucleotide synthetic oligonucleotide. Electroporation of 117 total embryos using the single-stranded DNA template across two experimental replicates produced thirteen live pups, four of which were verified positive for the full sequence modification, achieving editing rates between 30.0 and 33.3 percent. Conversely, electroporation of 101 embryos using the shorter oligonucleotide generated eight pups with only one exhibiting the correct knock-in, reflecting a 12.5 percent success rate. Sanger sequencing confirmed precise nucleotide conversion across the targeted codons, demonstrating that longer single-stranded DNA templates provide superior homology-directed repair efficiency for complex multi-residue humanization in NOD zygotes.
To rigorously delineate delivery boundaries, the investigators also tested cytoplasmic microinjection, delivering Cas9 and Gasdermin D guide RNA complexes beneath the zygote membrane while avoiding the pronuclei. Although cytoplasmic injection is technically less demanding and enables rapid embryo processing, transferring 206 cytoplasmically injected embryos into surrogate mothers produced twenty-six live pups, none of which carried the intended genetic modification. This zero percent success rate confirmed that the nuclear envelope presents an impermeable physical barrier to ribonucleoprotein complexes in NOD zygotes during early developmental stages. Consequently, pronuclear microinjection remains indispensable for large DNA constructs, bacterial artificial chromosomes exceeding 150 kilobases, and loci recalcitrant to electroporation, whereas electroporation provides an efficient, non-damaging alternative for validated guide RNAs and small homology donor templates.
To ensure practical utility for biomedical research, the team confirmed stable germline transmission and long-term strain integrity across all modified mouse lines. Edited founder males at eight weeks and females at six weeks were crossed with wild-type counterparts, and molecular screening of first-generation progeny confirmed successful germline transmission of the Gasdermin D, Trpm5, and humanized ACE2 alleles. Absence of protein expression was confirmed in homozygous knockout progeny, establishing complete functional gene disruption. All lines were maintained through wild-type breeding for three generations to dilute potential off-target genetic alterations identified through computational predictive algorithms before establishing homozygous breeding colonies and cryopreserving embryos and sperm. By establishing reliable superovulation in four-week-old donors, resolving pronuclear visualization timelines, and defining optimal delivery methods, this streamlined protocol reduces animal usage, conserves institutional resources, aligns directly with humane refinement principles, and dramatically accelerates the generation of advanced immunodeficient disease models.
Subject of Research: Direct CRISPR/Cas9 genome editing in NODShiLtJ mouse embryos
Article Title: A streamlined approach for gene editing in non-obese diabetes (NOD) mice via CRISPR/Cas9
Article References: Cho, K., Lionakis, M. S., & Khillan, J. S. (2026). A streamlined approach for gene editing in non-obese diabetes (NOD) mice via CRISPR/Cas9. Laboratory Animal Research, 42(1), Article 24. https://doi.org/10.1186/s42826-026-00281-x
Image Credits: AI Generated
DOI: 10.1186/s42826-026-00281-x
Keywords: CRISPR/Cas9, NODShiLtJ mice, non-obese diabetic mice, gene editing, pronuclear microinjection, electroporation, superovulation, Gasdermin D, Trpm5, ACE2 gene, knock-in humanization, embryo recovery, germline transmission, type 1 diabetes models, immunodeficiency, animal welfare refinement
News Source: Juliet Wilcox. (November 18, 2026). Optimized CRISPR Protocol Enables Direct Gene Editing in Non-Obese Diabetic Mice. Scienmag.



